Skip to main content

Table 2 Immune-related adverse events

From: Safety and efficacy of anti-PD-1 in patients with baseline cardiac, renal, or hepatic dysfunction

irAE

Grades 1/2 (N, %)

Grades 3/4 (N, %)

Arthralgias

1 (4 %)

0

Colitis

0

1 (4 %)

Conjunctivis

1 (4 %)

0

Diarrhea

1 (4 %)

0

Hepatitis

0

2 (7 %)

Hypothyroidism

4 (15 %)

0

Nephritis

2 (7 %)

0

Pruritis

1 (4 %)

0

Rash

3 (11 %)

0

Vitiligo

1 (4 %)

0